3,4-二羟基苯乙酸乙酯 | 83112-21-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 中文名称: 3,4-二羟基苯乙酸乙酯
• 英文名称: ethyl 2-(3,4-dihydroxyphenyl)acetate
• 英文别名: ethyl 3,4-dihydroxyphenylacetate；3,4-dihydroxyphenylacetic acid ethyl ester；L-158799
• CAS: 83112-21-4
• 化学式: C₁₀H₁₂O₄
• mdl: MFCD00564055
• 分子量: 196.203
• InChiKey: NFAJGEBLQZWGAF-UHFFFAOYSA-N

物化性质

• 沸点：
  345.8±27.0 °C(Predicted)
• 密度：
  1.260±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  66.8
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2918290000

反应信息

• 作为反应物：
  描述：

  3,4-二羟基苯乙酸乙酯 在 sodium tetrahydroborate 作用下， 生成 羟基酪醇
  参考文献：
  名称：

  Synthesis, Biological Evaluation, and Molecular Modeling of Oleuropein and Its Semisynthetic Derivatives as Cyclooxygenase Inhibitors

  摘要：

  Oleuropein, the main phenolic compound in virgin olive oil, and several of its derivatives such as oleuropein aglycone, hydroxytyrosol, and their respective acetylated lipophilic forms were obtained by simple and environmentally friendly semisynthetic protocols. The same molecules were then tested in vitro and in vivo, comparing their intriguing anti-COX-1 and anti-COX-2 properties to those of well-known anti-inflammatory drugs such as ibuprofen and celecoxib. Finally, molecular modeling experiments displaying the most probable binding modes within the classical binding clefts of the enzymes suggest the heme moiety as a potential alternative target.

  DOI：

  10.1021/jf9033305
• 作为产物：
  描述：

  4-氧代环己烷乙酸乙酯 在 碘 、 氧气 、 二甲基亚砜 作用下， 反应 12.0h， 以41%的产率得到3,4-二羟基苯乙酸乙酯
  参考文献：
  名称：

  简单环己酮转化为儿茶酚

  摘要：

  描述了在温和和简单的条件下，一种新型的 I2 催化的环己酮直接转化为取代的儿茶酚。仅使用 DMSO 作为溶剂、氧化剂和氧源即可实现多重氧化和脱氢芳构化过程，这种新颖的转变是显着的。这种不含金属的简单系统展示了一种合成高价值取代儿茶酚的通用方案，因此简化了用于药物发现的生物重要分子的合成和修饰。

  DOI：

  10.1021/jacs.6b07269

文献信息

• Small Molecule Inhibitors of the BfrB–Bfd Interaction Decrease <i>Pseudomonas aeruginosa</i> Fitness and Potentiate Fluoroquinolone Activity
  作者：Achala N. D. Punchi Hewage、Huili Yao、Baskar Nammalwar、Krishna Kumar Gnanasekaran、Scott Lovell、Richard A. Bunce、Kate Eshelman、Sahishna M. Phaniraj、Molly M. Lee、Blake R. Peterson、Kevin P. Battaile、Allen B. Reitz、Mario Rivera

  DOI：10.1021/jacs.9b00394

  日期：2019.5.22

  inhibitors of the BfrB–Bfd protein–protein interaction. The process was initiated by screening a fragment library and followed by obtaining the structure of a fragment hit bound to BfrB. The structural insights were used to develop a series of 4-(benzylamino)- and 4-((3-phenylpropyl)amino)-isoindoline-1,3-dione analogs that selectively bind BfrB at the Bfd binding site. Challenging P. aeruginosa cells with

  储铁蛋白细菌铁蛋白 (BfrB) 是细菌铁稳态的核心。从 BfrB 中动员铁，这需要通过同源铁氧还蛋白 (Bfd) 结合，对于调节铜绿假单胞菌中的细胞溶质铁水平至关重要。本文描述了 BfrB-Bfd 蛋白质-蛋白质相互作用的小分子抑制剂的结构引导开发。该过程通过筛选片段文库开始，然后获得与 BfrB 结合的片段命中结构。结构见解用于开发一系列 4-(苄基氨基)-和 4-((3-苯基丙基)氨基)-isoindoline-1,3-dione 类似物，它们在 Bfd 结合位点选择性结合 BfrB。用 4 取代异二氢吲哚类似物挑战铜绿假单胞菌细胞显示出剂量依赖性生长表型。进一步的研究确定，这些类似物引发了一种pyoverdin 过度生产表型，这与 BfrB-Bfd 相互作用的阻断和随之而来的铁在 BfrB 中的不可逆积累一致，伴随着细胞质中铁的消耗。通过在天然 PAGE 凝胶上分离的铜绿假单胞菌细胞裂解物中的
• Vanilloid Receptor Ligands, Pharmaceutical Compositions Containing Them, Process for Making Them, and Use Thereof for Treating Pain and Other Conditions
  申请人：FRANK Robert

  公开号：US20090156590A1

  公开（公告）日：2009-06-18

  Vanilloid receptor ligand compounds corresponding to formula I: pharmaceutical compositions containing such compounds, a process for producing such compounds, and methods of using such compounds for treating or inhibiting pain and various other disorders or conditions.

  与公式I相对应的辣椒素受体配体化合物：含有这种化合物的药物组合物，生产这种化合物的方法，以及使用这种化合物治疗或抑制疼痛和各种其他疾病或症状的方法。
• [EN] SMALL MOLECULE INHIBITORS OF THE BFRB:BFD INTERACTION<br/>[FR] INHIBITEURS À PETITES MOLÉCULES DE L'INTERACTION BFRB-BFD
  申请人：UNIV KANSAS

  公开号：WO2020117832A1

  公开（公告）日：2020-06-11

  The present technology provides compounds of Formula I and related methods for treating a bacterial infection as well as methods for inhibiting interaction of a bacterioferritin and a bacterioferritin-associated ferredoxin.

  目前的技术提供了Formula I化合物以及相关方法，用于治疗细菌感染，以及抑制细菌铁蛋白和细菌铁蛋白相关的叶绿素蛋白之间的相互作用的方法。
• Natural compounds and their derivatives for the prevention and treatment of cardiovascular, hepatic and renal diseases and for cosmetic applications
  申请人：——

  公开号：US20030225160A1

  公开（公告）日：2003-12-04

  The present invention refers to the use of phenolic compounds and their derivatives represented by formula I wherein R 1 and R 2 are selected from among: OH, OCOalkyl, or OCOalkenyl, and R 3 is either H, OH, OCOalkyl or OCOalkenyl, wherein the alkyl or alkenyl chains present from 2 to 22 carbon atoms and wherein at least one OCOalkyl or OCOalkenyl group is present in the structure, for the prevention and treatment of cardiovascular, hepatic or renal diseases, as well as to their cosmetic applications, to compositions that include these compounds and to some novel phenolic compounds and derivatives.

  本发明涉及酚类化合物及其衍生物的使用，其表示为公式I，其中R1和R2从以下选项中选择：OH、OCO烷基或OCO烯基，R3为H、OH、OCO烷基或OCO烯基，其中烷基或烯基链含有2至22个碳原子，并且结构中至少存在一个OCO烷基或OCO烯基基团，用于预防和治疗心血管、肝脏或肾脏疾病，以及它们的化妆品应用，包括这些化合物的组合物和一些新型酚类化合物和衍生物。
• Natural products and derivatives thereof for protection against neurodegenerative diseases
  申请人：——

  公开号：US20030236202A1

  公开（公告）日：2003-12-25

  The invention relates to the use of phenolic compounds and derivatives thereof for protection against neurodegenerative diseases, to compositions comprising these compounds, and to some novel phenolic compounds.

  该发明涉及利用酚类化合物及其衍生物来保护免受神经退行性疾病的影响，涉及包含这些化合物的组合物，以及一些新型酚类化合物。